352 results on '"Ouzan, Denis"'
Search Results
2. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis
3. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)
4. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
5. Large-scale screening of lipase acid deficiency in at risk population
6. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
7. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
8. Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease
9. Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study
10. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
11. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease
12. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.
13. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
14. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
15. Screening for hepatic fibrosis in primary care by FIB-4 score, followed in second line f the ELF (enhanced liver fibrosis) test: what are the best thresholds?
16. Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test
17. Supplementary Tables from HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
18. Suppl_Figure1 from HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
19. Data from HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
20. Supplementary Figure Legend from HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
21. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
22. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset
23. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
24. ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts
25. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset
26. Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: A prospective multicenter cohort
27. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study
28. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension
29. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
30. HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers
31. Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists
32. Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose?
33. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset
34. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)
35. An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).
36. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)
37. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
38. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients
39. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin
40. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions
41. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
42. FRI-481 - Screening for hepatic fibrosis in primary care by FIB-4 score, followed in second line f the ELF (enhanced liver fibrosis) test: what are the best thresholds?
43. SAT-445 - Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test
44. Malades atteints d’hépatite chronique C non répondeurs : définitions de la non-réponse et stratégies thérapeutiques
45. Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy
46. Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status
47. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
48. Add-on of peg interferon to a stable nucleoside regimen led to loss of HBs Ag in chronic hepatitis HBeAg negative patients: 465
49. Impact of entecavir (ETV) on liver fibrosis and activity as assessed by the non-invasive methods of FibroTest-ActiTest (FT-AT) and liver stiffness measurements (LSM) in patients with chronic hepatitis B (CHB): 450
50. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.